Zobrazeno 1 - 10
of 61
pro vyhledávání: ''
Publikováno v:
Drug Design, Development and Therapy
Yueyue Liu, Qian Zhang, Chao Lu, Wei Hu Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, 230601, People’s Republic of ChinaCorrespondence: Chao Lu; Wei HuDepartment of Clinical Pharmacology, The Second Ho
Autor:
Guanyang Lin, Chenxiang Wang, Yuzhen Wang, Ziye Zhou, Congcong Wen, Suili Yang, Xiaoshan Zhang
Publikováno v:
Drug Design, Development and Therapy
Suili Yang,1,* Xiaoshan Zhang,2,3,* Yuzhen Wang,2,3 Congcong Wen,4 Chenxiang Wang,3 Ziye Zhou,5 Guanyang Lin3 1Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 2Col
Autor:
Joo Youn Cho, Yu Kyung Kwon, Seo Hyun Yoon, In-Jin Jang, Seung-Hwan Lee, Inseung Jeon, Jaeseong Oh, Kyung Sang Yu
Publikováno v:
Drug Design, Development and Therapy. 15:1735-1747
Inseung Jeon,1,* Jaeseong Oh,1,* Yu-Kyung Kwon,2 Seo Hyun Yoon,1 Joo-Youn Cho,1 In-Jin Jang,1 Kyung-Sang Yu,1 SeungHwan Lee1 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Rep
Publikováno v:
Drug Design, Development and Therapy
Chen-jian Zhou,1 Hui-jun Wang,2 Chun-yan Zhou,2 Chao-fan Li,2 Ming-Jia Zhu,2 Xiang-jun Qiu2 1Department of Pharmacy, Wenzhou Central Hospital, Wenzhou, 325027, People’s Republic of China; 2School of Basic Medical Sciences, Henan University of Scien
Autor:
Lei Sheng, Mengjie Yang, Chunjiu Zhong, Wei-Li Chen, Chao Liu, Xue-Ning Li, Ping-ping Lin, Wei Cao, Hanjing Chen, Fei Yuan, Hui Li, Hong-Rong Xu
Publikováno v:
Drug Design, Development and Therapy
Lei Sheng,1,* Wei Cao,2,* Pingping Lin,3 Weili Chen,1 Hongrong Xu,1 Chunjiu Zhong,4 Fei Yuan,1 Hanjing Chen,1 Hui Li,1 Chao Liu,1 Mengjie Yang,1 Xuening Li1 1Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, 200032,
Publikováno v:
Drug Design, Development and Therapy
Weihong Li,1,* Yanrong Wang,1,* Yingzi Pei,2 Yue Xia2 1GCP Office of Cangzhou Central Hospital, Cangzhou, Hebei, 061000, People’s Republic of China; 2Research Center of Beijing Fuyuan Pharmaceutical Co., Ltd. (Formerly Beijing Wansheng Pharmaceutic
Mini-Tablets versus Nanoparticles for Controlling the Release of Amoxicillin: In vitro/In vivo Study
Autor:
Hessah S Alhawas, Siham Abdoun, Dalia A Gaber, Amal Al-Subaiyel, Fatimah A Alfadhel, Rehab M Alsawi
Publikováno v:
Drug Design, Development and Therapy. 14:5405-5418
Introduction Controlling the drug release from the dosage form at a definite rate is the main challenge for a successful oral controlled-release drug delivery system. In this study, mini-tablets (MTs) and lipid/polymer nanoparticles (LPNs) of lipid p
Publikováno v:
Drug Design, Development and Therapy. 14:5179-5187
Purpose Evogliptin, a dipeptidyl peptidase-4 inhibitor, and glimepiride, a sulfonylurea, are used to treat type 2 diabetes mellitus. In this study, we aimed to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between evogliptin
Autor:
Shuanghu Wang, Quan Zhou, Deru Meng, Hui Jiang, Feifei Chen, Peiwu Geng, Yunfang Zhou, Dapeng Dai, Jia Xu
Publikováno v:
Drug Design, Development and Therapy. 14:4815-4824
Purpose The purpose of the present study was to investigate the effects of vonoprazan on the pharmacokinetics of venlafaxine in vitro and in vivo. Methods The mechanism underlying the inhibitory effect of vonoprazan on venlafaxine was investigated us
Autor:
Giuseppe Privitera, Lorenzo Bertani, Luigi Giovanni Papparella, Antonio Gasbarrini, Franco Scaldaferri, Daniela Pugliese, Gian Lodovico Rapaccini, Sara Onali, Francesco Costa, Linda Ceccarelli, Barbara Tolusso, Elisa Gremese, Alessandro Armuzzi, Luisa Guidi, Simona Maltinti, Clara Di Mario
Publikováno v:
Expert Opinion on Biological Therapy. 21:97-104
Switching from IFX originator to CT-P13 is safe; however, little data on immunogenicity exists.Consecutive IBD patients on IFX originator were switched to CT-P13 and followed-up for 12 months. Clinical activity, infliximab trough levels (ITLs), anti-